Biosergen AB (publ) (8N10)

Overview

Biosergen AB (publ) is a pioneering biotechnology company dedicated to the development of novel antifungal therapies specifically tailored for the treatment of invasive fungal infections. These conditions are particularly perilous for immunocompromised individuals, including those with AIDS, cancer, or patients post-transplant. The company’s flagship product, BSG005, is a genetically enhanced polyene macrolide that is designed to provide enhanced safety and efficacy by not only inhibiting fungal growth but actively killing fungal pathogens. The innovation originated from research conducted at the Norwegian University of Science and Technology in collaboration with SINTEF. With a focus on a wide-ranging spectrum of fungal genera, Biosergen addresses urgent healthcare needs within vulnerable patient populations. The company engages in international collaborations, exemplified by its partnership with Alkem Laboratories Limited, to further clinical studies and facilitate the introduction of its treatments in global markets. It holds patents for its technology effective until 2043 and has received orphan drug designation from the FDA, reflecting its commitment to addressing rarified and life-threatening fungal conditions. Through its advanced research and development efforts, Biosergen plays a crucial role in redefining antifungal drug innovation, with the overarching goal of enhancing patient outcomes and quality of life.

Products and Services

• BSG005

  BSG005 is the lead product of Biosergen AB, designed as a genetically modified polyene macrolide. It differentiates itself from traditional therapies by effectively targeting and killing fungal pathogens instead of simply inhibiting their growth, providing a potent and safer treatment option for patients suffering from invasive fungal infections, particularly in immunocompromised demographics.

• Clinical Development Collaborations

  Biosergen actively collaborates with key international partners, most notably Alkem Laboratories Limited, to progress clinical studies. Through these partnerships, the company aims to accelerate the development and market entry of its innovative therapies, ensuring that they can reach patients who need them most in a timely manner.

• Patent Protection

  The company has secured patents for its proprietary technology, protecting its innovations in antifungal treatments until 2043. This intellectual property is integral to maintaining a competitive edge in the biotechnology sector while fostering further research and development initiatives.

• Orphan Drug Status

  Biosergen's BSG005 has been granted orphan drug status by the FDA, recognizing the significant unmet medical need in treating rare and life-threatening fungal infections. This designation not only provides regulatory advantages but also underscores the company’s commitment to addressing critical health challenges faced by vulnerable patient populations.